A Phase 2 interventional study of LY3819469 and Placebo in Lipoprotein Disorder, sponsored by Eli Lilly and Company. Completed at 80 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to screening and randomization and expected to remain on a stable regimen through the end of the Treatment and Assessment Period:
Male and/or Female
Exclusion Criteria:
Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 16 milligrams (mg) of LY3819469 on day 1 and day 180, administered as a subcutaneous (SC) injection.
Drug: LY3819469
Participants received 96 mg of LY3819469 on day 1 and day 180, administered as a SC injection.
Drug: LY3819469
Participants received 400 mg of LY3819469 on day 1 and day 180, administered as a SC injection.
Drug: LY3819469
Participants received 400 mg of LY3819469 on day 1 and placebo on day 180, administered as a SC injection.
Drug: LY3819469 · Drug: Placebo
Participants received placebo on day 1 and day 180, administered as a SC injection.
Drug: Placebo
Administered SC
Administered SC
Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180
LPa levels were assessed using Immuno turbidimetric method. Percent change is calculated as: Percent Change=\[(Lp(a) at Time Point-Lp(a) at Baseline)/Lp(a) at Baseline\]×100 Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.
Time frame: Baseline, Days 60 - 180
Percent Change From Baseline in Time Averaged Lp(a) Over Days 240-360
LPa levels were assessed using Immuno turbidimetric method. LS mean was determined using MMRM model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures.. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.
Time frame: Baseline, Days 240 - 360
Percentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 60, 180
Percentage of Participants Achieving Lp(a) \<125 and \<75 Nanomole/Liter (nmol/L) at Days 60, 180 is reported.
Time frame: Days 60, 180
Percentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 240, 360, and 540
Percentage of Participants Achieving Lp(a) \<125 and \<75 Nanomole/Liter (Nmol/L) at Days 240, 360, and 540 is reported.
Time frame: Days 240, 360, and 540
Percent Change From Baseline in Lp(a)
LS mean was determined using MMRM model with log(Actual Measurement/Baseline) = log (Baseline) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.
Time frame: Baseline, Days 60, 180, 240, 360, and 540
Percent Change From Baseline in Apolipoprotein B (ApoB)
LS mean was determined using MMRM model with log (Actual Measurement/Baseline) = log(Baseline) + Baseline Lp(a) stratum (\<275 nmol/L vs. \>=275 nmol/L) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.
Time frame: Baseline, Days 60, 180, 240, 360, and 540
Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)
hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation. LS mean was determined using MMRM model with log (Actual Measurement/Baseline) = log(Baseline) + Baseline Lp(a) stratum (\<275 nmol/L vs. \>=275 nmol/L) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.
Time frame: Baseline, Days 60, 180, 240, 360, and 540
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3819469
AUC was computed using the population PK model. Therefore, the concentrations are simulated from time 0 to infinity to estimate AUC for each participant. The timeframe reflects the PK timepoints that were collected to develop the population PK. Although this is a multiple dose study, the plasma PK is very short, so AUC0-180days is equivalent to AUC0-infinity.
Time frame: Day 1: 0.5 hours, 4-9 hours post-dose; Day 180: 24-36 hours post-dose
| Milestone | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo |
|---|---|---|---|---|---|
| Started | 36 | 74 | 69 | 72 | 69 |
| Received at least one dose of study drug | 36 | 74 | 69 | 72 | 69 |
| Full analysis set (fas) | 36 | 74 | 69 | 72 | 69 |
| Efficacy analysis set (eas) | 36 | 74 | 69 | 72 | 69 |
| Completed | 35 | 74 | 67 | 70 | 66 |
| Not completed | 1 | 0 | 2 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 2 | 2 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Participant travelled abroad | 0 | 0 | 0 | 0 | 1 |
LPa levels were assessed using Immuno turbidimetric method. Percent change is calculated as: Percent Change=\[(Lp(a) at Time Point-Lp(a) at Baseline)/Lp(a) at Baseline\]×100 Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.
| percent change | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 | -39.0 ± 7.37 | -74.4 ± 2.16 | -93.7 ± 0.38 | 3.1 ± 8.99 |
LPa levels were assessed using Immuno turbidimetric method. LS mean was determined using MMRM model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures.. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.
| percent change | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Time Averaged Lp(a) Over Days 240-360 | -38.7 ± 7.66 | -77.4 ± 1.97 | -95.0 ± 0.45 | -76.7 ± 2.06 | 0.3 ± 9.07 |
Percentage of Participants Achieving Lp(a) \<125 and \<75 Nanomole/Liter (nmol/L) at Days 60, 180 is reported.
| percentage of participants | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) | Placebo |
|---|---|---|---|---|
| Lp(a) <125 nmol/L: Day 60 | 37.14 | 86.30 | 97.81 | 0.00 |
| Lp(a) <125 nmol/L: Day 180 | 14.29 | 58.33 | 90.15 | 0.00 |
| Lp(a) <75 nmol/L: Day 60 | 14.29 | 64.38 | 96.35 | 0.00 |
| Lp(a) <75 nmol/L: Day 180 | 8.57 | 33.33 | 81.06 | 0.00 |
Percentage of Participants Achieving Lp(a) \<125 and \<75 Nanomole/Liter (Nmol/L) at Days 240, 360, and 540 is reported.
| percentage of participants | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo |
|---|---|---|---|---|---|
| Lp(a) <125 nmol/L: Day 240 | 36.36 | 88.06 | 98.41 | 78.79 | 1.56 |
| Lp(a) <125 nmol/L: Day 360 | 24.24 | 58.82 | 88.89 | 59.38 | 0.00 |
| Lp(a) <125 nmol/L: Day 540 | 9.38 | 32.31 | 75.41 | 35.48 | 0.00 |
| Lp(a) <75 nmol/L: Day 240 | 18.18 | 76.12 | 96.83 | 65.15 | 1.56 |
| Lp(a) <75 nmol/L: Day 360 | 6.06 | 41.18 | 82.54 | 42.19 | 0.00 |
| Lp(a) <75 nmol/L: Day 540 | 0.00 | 16.92 | 45.90 | 16.13 | 0.00 |
LS mean was determined using MMRM model with log(Actual Measurement/Baseline) = log (Baseline) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares) as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.
| percent change | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo |
|---|---|---|---|---|---|
| Baseline, Day 60 | -46.2 ± 6.04 | -80.4 ± 1.53 | -95.4 ± 0.26 | -95.4 ± 0.26 | 2.2 ± 8.29 |
| Baseline, Day 180 | -30.5 ± 9.17 | -65.3 ± 3.20 | -90.5 ± 0.64 | -90.5 ± 0.64 | 2.2 ± 9.78 |
| Baseline, Day 240 | -47.7 ± 6.63 | -84.8 ± 1.35 | -96.8 ± 0.23 | -84.9 ± 1.09 | -0.8 ± 9.10 |
| Baseline, Day 360 | -30.8 ± 9.19 | -67.7 ± 2.99 | -91.1 ± 0.69 | -68.1 ± 2.46 | -0.9 ± 9.53 |
| Baseline, Day 540 | -18.7 ± 8.56 | -45.1 ± 4.04 | -73.8 ± 1.69 | -52.8 ± 3.04 | 1.3 ± 7.76 |
LS mean was determined using MMRM model with log (Actual Measurement/Baseline) = log(Baseline) + Baseline Lp(a) stratum (\<275 nmol/L vs. \>=275 nmol/L) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.
| percent change | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo |
|---|---|---|---|---|---|
| Baseline, Day 60 | -10.2 ± 3.07 | -11.8 ± 2.10 | -13.9 ± 1.49 | -13.9 ± 1.49 | 0.2 ± 2.47 |
| Baseline, Day 180 | -7.0 ± 3.49 | -9.6 ± 2.37 | -12.6 ± 1.68 | -12.6 ± 1.68 | 1.3 ± 2.78 |
| Baseline, Day 240 | -7.6 ± 3.24 | -13.8 ± 2.11 | -14.0 ± 1.98 | -9.0 ± 2.05 | 1.8 ± 2.58 |
| Baseline, Day 360 | -2.9 ± 3.56 | -8.1 ± 2.35 | -10.4 ± 2.20 | -4.6 ± 2.33 | 4.3 ± 2.77 |
| Baseline, Day 540 | 1.4 ± 3.55 | -0.6 ± 2.42 | -9.1 ± 2.13 | -0.9 ± 2.31 | 4.3 ± 2.64 |
hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation. LS mean was determined using MMRM model with log (Actual Measurement/Baseline) = log(Baseline) + Baseline Lp(a) stratum (\<275 nmol/L vs. \>=275 nmol/L) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment\*Time (Type III sum of squares as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.
| percent change | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo |
|---|---|---|---|---|---|
| Baseline, Day 60 | -15.4 ± 13.94 | 0.1 ± 11.22 | -1.9 ± 8.00 | -1.9 ± 8.00 | 2.1 ± 11.87 |
| Baseline, Day 180 | 10.6 ± 18.22 | -6.5 ± 10.59 | 16.2 ± 9.72 | 16.2 ± 9.72 | 10.3 ± 13.17 |
| Baseline, Day 240 | -3.4 ± 13.02 | -8.4 ± 8.60 | 7.3 ± 9.50 | -1.2 ± 8.67 | 9.1 ± 10.52 |
| Baseline, Day 360 | 43.6 ± 25.21 | 13.5 ± 13.89 | 10.4 ± 12.90 | 32.3 ± 15.36 | 10.8 ± 14.04 |
| Baseline, Day 540 | -7.7 ± 14.93 | -1.2 ± 11.19 | 0.9 ± 11.12 | 14.1 ± 12.65 | 0.1 ± 11.89 |
AUC was computed using the population PK model. Therefore, the concentrations are simulated from time 0 to infinity to estimate AUC for each participant. The timeframe reflects the PK timepoints that were collected to develop the population PK. Although this is a multiple dose study, the plasma PK is very short, so AUC0-180days is equivalent to AUC0-infinity.
| nanogram*hour per milliliter (ng*hr/mL) | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3819469 | 1853 ± 36 | 10110 ± 26 | 55242 ± 42 | 46633 ± 13 |
Collected over Baseline Up to Day 540. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 16 mg LY3819469 | 1/36 (2.8%) | 1/36 (2.8%) | 14/36 (38.9%) |
| 96 mg LY3819469 | 0/74 (0%) | 9/74 (12.2%) | 25/74 (33.8%) |
| 400 mg LY3819469 | 0/69 (0%) | 11/69 (15.9%) | 34/69 (49.3%) |
| 400 mg LY3819469 + Placebo | 0/72 (0%) | 8/72 (11.1%) | 35/72 (48.6%) |
| Placebo | 0/69 (0%) | 6/69 (8.7%) | 26/69 (37.7%) |
| Event | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo |
|---|---|---|---|---|---|
| Breast cancer femaleNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 1/35 | 0/35 | 0/27 | 0/32 |
| Cardiac failureCardiac disorders | 1/36 | 0/74 | 0/69 | 0/72 | 0/69 |
| Cardiac deathGeneral disorders | 1/36 | 0/74 | 0/69 | 0/72 | 0/69 |
| HyponatraemiaMetabolism and nutrition disorders | 1/36 | 0/74 | 0/69 | 0/72 | 0/69 |
| Atrial fibrillationCardiac disorders | 0/36 | 0/74 | 0/69 | 0/72 | 1/69 |
| CellulitisInfections and infestations | 0/36 | 1/74 | 1/69 | 0/72 | 0/69 |
| Complicated appendicitisInfections and infestations | 0/36 | 0/74 | 1/69 | 0/72 | 0/69 |
| DiverticulitisInfections and infestations | 0/36 | 0/74 | 1/69 | 0/72 | 0/69 |
| Pilonidal diseaseInfections and infestations | 0/36 | 0/74 | 1/69 | 0/72 | 0/69 |
| SepsisInfections and infestations | 0/36 | 0/74 | 1/69 | 0/72 | 0/69 |
| Event | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/36 | 6/74 | 5/69 | 10/72 | 6/69 |
| Injection site reactionGeneral disorders | 0/36 | 6/74 | 8/69 | 6/72 | 1/69 |
| InfluenzaInfections and infestations | 4/36 | 7/74 | 2/69 | 4/72 | 2/69 |
| Ovarian cystReproductive system and breast disorders | 1/9 | 0/35 | 0/35 | 0/27 | 0/32 |
| Covid-19Infections and infestations | 2/36 | 1/74 | 5/69 | 4/72 | 7/69 |
| Upper respiratory tract infectionInfections and infestations | 0/36 | 5/74 | 3/69 | 6/72 | 0/69 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/36 | 2/74 | 3/69 | 6/72 | 2/69 |
| DiarrhoeaGastrointestinal disorders | 0/36 | 0/74 | 4/69 | 2/72 | 3/69 |
| Urinary tract infectionInfections and infestations | 1/36 | 2/74 | 4/69 | 2/72 | 3/69 |
| Alanine aminotransferase increasedInvestigations | 0/36 | 0/74 | 4/69 | 0/72 | 0/69 |
All randomized participants.
| Age, Continuous(years) | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 62.6 ± 10.55 | 63.8 ± 9.9 | 61.4 ± 10.93 | 62.2 ± 9.65 | 63.5 ± 8.42 | 62.7 ± 9.84 |
| Sex: Female, Male(Participants) | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 9 | 35 | 35 | 27 | 32 | 138 |
| Male | 27 | 39 | 34 | 45 | 37 | 182 |
| Ethnicity (NIH/OMB)(Participants) | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 8 | 10 | 17 | 2 | 44 |
| Not Hispanic or Latino | 28 | 66 | 59 | 55 | 67 | 275 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 1 | 2 | 0 | 5 |
| Asian | 3 | 13 | 13 | 8 | 10 | 47 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 2 | 2 | 0 | 7 |
| White | 30 | 58 | 53 | 60 | 59 | 260 |
| More than one race | 0 | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo | Total |
|---|---|---|---|---|---|---|
| Argentina | 5 | 6 | 5 | 6 | 2 | 24 |
| Netherlands | 2 | 11 | 9 | 7 | 7 | 36 |
| Romania | 3 | 3 | 2 | 4 | 1 | 13 |
| United States | 8 | 17 | 19 | 19 | 24 | 87 |
| China | 0 | 3 | 1 | 3 | 3 | 10 |
| Japan | 3 | 10 | 11 | 5 | 5 | 34 |
| Denmark | 4 | 4 | 5 | 4 | 12 | 29 |
| Mexico | 2 | 0 | 2 | 4 | 0 | 8 |
| Germany | 5 | 12 | 8 | 6 | 10 | 41 |
| Spain | 4 | 8 | 7 | 14 | 5 | 38 |
| Lipoprotein(a) [Lp(a)] level(Nanomole/Liter (nmol/L)) | 16 mg LY3819469 | 96 mg LY3819469 | 400 mg LY3819469 | 400 mg LY3819469 + Placebo | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 267.63 ± 81.80 | 278.86 ± 79.53 | 276.66 ± 100.68 | 279.98 ± 93.50 | 266.62 ± 91.31 | 274.74 ± 89.98 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2022 to primary completion in Oct 2023, 12 months.
Results were first posted in May 2025, 1 year 7 months after primary completion. A results delay was requested in Apr 2024.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lepodisiran